GLG News by Cosmetic Dermatologists in Private Practice (US)
Articles with lock require a subscription to GLG News |
Request a free trial
March 19, 2008Ustekinumab shows promise
Analysis of: Novel Biologic Agent Proves Highly Effective in Severe Plaque Psoriasis | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Centocors new product- Ustekinumab /CNTO 1275 had impressive results in the recent PHOENIX trials and the application is under review at the FDA. The PASI score reductions are superior to the exiting agents such as Enbrel and Humira, and are comparable to those of the other Centocor product- Remicade...
March 7, 2008Renovo's Juvista product holds promose
Analysis of: Juvista Phase II Trial Results in Scar Revision and Breast Augmentation Surgery | www.renovo.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that this is an under served market. Current scar reduction products are only modestly effective, or not effective at all. An agent which has a "70% "reported reduction in scar appearance,is safe, and only has to be used a few times has a large market and will be successful....
March 6, 2008Phosphagenics Topical Retinoic Acid Clinical Trial Initiated
Analysis of: Phosphagenics Initiates US Clinical Trials For Its Topical Retinoic Acid | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This new delivery system from Phosphagenics for enhancing absorption and reducing irritation will have moderate effect on the retinoid market. Retinoic Acid use has been in decline not so much because of irritation, but because of the introduction of more efficacious retinoids like Tazorac and Differin...
February 12, 2008FDA Botox warning unlikely to limit cosmetic use
Analysis of: FDA Issues Warning About Botox Deaths | www.pharmalot.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The recent FDA warning on Botox is unlikely to limit the cosmetic use of the product because the dose is relatively low. The warning only applies to significantly higher doses in patients with neuromuscular conditions like cerebral palsy. Serious adverse events like allergic reactions are very...
February 8, 2008Botox competitors to make market interesting
Analysis of: Efficacy of Botulinum Toxin Does Not Sag Over Time | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Botox is highly effective cosmetic product, albeit not long lasting. Patient satisfaction is high, and the cost is still not prohibitive. However the predictable and not always justified increases in price have forced many physicians to eagerly await the newer agents. The include products from...
February 8, 2008Enbrel effective in pediatric psoriasis
Analysis of: New Study Reports Enbrel (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents | www.wyeth.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This study will expand the use of Enbrel in newer populations. this is important in that Humira just received approval for adults, and the market has become more competitive. This is good news for children with severe resistant psoriasis.
December 17, 2007
Cost is key, but not enough!
Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
Cost is key, but not enough!
Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
Lowering cost of Botox is key, but not enough to induce patients to undergo Botox treatments.
December 17, 2007Centecor Ustekinumab- an impressive product for psoriasis
Analysis of: Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis | www.jnj.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The new Centecor psoriasis product, Ustekinumab, is impressive in its efficacy. The PASI 75 reduction is equal or surpasses Remicade, the current leader in efficacy in psoriasis. This product has the advantage of being a self administered injection at home, rather than a prolonged IV injection...
December 17, 2007Medicis and Revance topical botox promising.
Analysis of: Medicis and Revance Announce Strategic Collaboration | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This topical Botox product is promising in that it would require no injection, and would be better accepted by patients. Medicis investment in the company is a wise adjunct to their Reloxin product, which was recently submitted to the FDA. Both these products would offer significant competition...
December 13, 2007
Reloxin Gives Allergan's Botox A Run for the Money!
Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
Reloxin Gives Allergan's Botox A Run for the Money!
Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
For too long Allergan has monopolized the therapeutic and cosmetic market of botulinum toxin type A, and has taken full advantage of that monopoly by raising the price of Botox almost biannually. Reloxin studies are very favorable when compared to Botox, and may even surpass it in one or two aspects....
Previous Page : 1 2 3 4 5 6 7 8 Next21 to 30 of 74
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Personal medicine is goal of Eli Lilly & Co.
www.azcentral.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008